CLINICAL TRIALS PROFILE FOR FENOFIBRATE (MICRONIZED)
✉ Email this page to a colleague
All Clinical Trials for FENOFIBRATE (MICRONIZED)
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00309712 ↗ | Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study | Completed | Abbott | N/A | 2002-08-01 | The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy. |
| NCT00309712 ↗ | Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study | Completed | Merck Sharp & Dohme Corp. | N/A | 2002-08-01 | The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy. |
| NCT00309712 ↗ | Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study | Completed | Intermountain Health Care, Inc. | N/A | 2002-08-01 | The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy. |
| NCT00359281 ↗ | Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents | Completed | Aegerion Pharmaceuticals, Inc. | Phase 2 | 2006-03-01 | This phase II, open-label research study was conducted in 129 healthy volunteers. Each subject will be given one initial oral dose of one of 7 FDA-approved medications (probe drugs), followed by a 7 day period where subjects receive the study medication AEGR-733 at 10 or 60 mg. On study day 8 subjects will receive the second oral dose of the same probe drug that was given on day 1 and a last dose of AEGR-733 (total of 7 doses).Subjects will return in 1 week for a final safety visit. Each FDA- approved probe drug will be given to ten (10) or fifteen (15) subjects. Safety, pharmacokinetic and pharmacodynamic assessments will be performed. |
| NCT00422396 ↗ | Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis | Completed | Abbott | N/A | 2001-01-01 | This is a randomized placebo controlled clinical trial designed to investigate the effects of micronized fenofibrate on fasting and postprandial lipoproteins, oxidized fatty acids and lipoproteins, inflammatory mediators and thrombotic factors among hypertriglyceridemic individuals with two or more other characteristics of the metabolic syndrome. |
| NCT00422396 ↗ | Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis | Completed | University of Michigan | N/A | 2001-01-01 | This is a randomized placebo controlled clinical trial designed to investigate the effects of micronized fenofibrate on fasting and postprandial lipoproteins, oxidized fatty acids and lipoproteins, inflammatory mediators and thrombotic factors among hypertriglyceridemic individuals with two or more other characteristics of the metabolic syndrome. |
| NCT01010516 ↗ | Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia | Unknown status | University of Ioannina | Phase 4 | 2009-10-01 | Statin therapy does not fully eliminate the cardiovascular disease (CVD) risk associated with low high density lipoprotein-C (HDL-C) and high triglyceride levels. It is currently unknown what would be the best treatment option for patients with mixed hyperlipidemia who fail to meet their lipid targets with statin monotherapy at conventional does, i.e. high dose rosuvastatin or conventional statin dose plus micronized fenofibrate or conventional statin dose plus niacin/laropiprant. The aim of the present study is to compare the efficacy of high-dose rosuvastatin vs conventional statin dose plus micronized fenofibrate vs conventional statin dose plus extended-release niacin/laropiprant on lipid profile in patients with mixed hyperlipidemia. The primary efficacy endpoint will be changes in non-HDL-C levels at 6 months after treatment initiation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FENOFIBRATE (MICRONIZED)
Condition Name
Clinical Trial Locations for FENOFIBRATE (MICRONIZED)
Trials by Country
Clinical Trial Progress for FENOFIBRATE (MICRONIZED)
Clinical Trial Phase
Clinical Trial Sponsors for FENOFIBRATE (MICRONIZED)
Sponsor Name
